At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Post-Market Trading 11-15 19:27:56 EST
3.38
+0.08
+2.42%
盘后3.42
+0.04+1.19%
16:13 EST
High3.42
Low3.19
Vol23.74K
Open3.42
D1 Closing3.30
Amplitude6.97%
Mkt Cap4.28M
Tradable Cap3.46M
Total Shares1.27M
T/O79.20K
T/O Rate2.32%
Tradable Shares1.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Pasithea Therapeutics files to sell 3.74M shares of common stock for holders
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (Pk), and Preliminary Efficacy Data From Its Phase 1 Clinical Trial of Pas-004 in Advanced Cancer
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.